Frontiers in Cardiovascular Medicine (Mar 2022)
Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment
- Faisal Alandejani,
- Abdul Hameed,
- Abdul Hameed,
- Euan Tubman,
- Samer Alabed,
- Samer Alabed,
- Yousef Shahin,
- Yousef Shahin,
- Robert A. Lewis,
- Robert A. Lewis,
- Krit Dwivedi,
- Aqeeb Mahmood,
- Jennifer Middleton,
- Jennifer Middleton,
- Lisa Watson,
- Dheyaa Alkhanfar,
- Christopher S. Johns,
- Smitha Rajaram,
- Pankaj Garg,
- Robin Condliffe,
- Charlie A. Elliot,
- A. A. Roger Thompson,
- A. A. Roger Thompson,
- Alexander M. K. Rothman,
- Alexander M. K. Rothman,
- Alexander M. K. Rothman,
- Athanasios Charalampopoulos,
- Allan Lawrie,
- Jim M. Wild,
- Jim M. Wild,
- Andrew J. Swift,
- Andrew J. Swift,
- David G. Kiely,
- David G. Kiely,
- David G. Kiely
Affiliations
- Faisal Alandejani
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Abdul Hameed
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Abdul Hameed
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- Euan Tubman
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Samer Alabed
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Samer Alabed
- Institute for in silico Medicine (INSIGNEO), University of Sheffield, Sheffield, United Kingdom
- Yousef Shahin
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Yousef Shahin
- Institute for in silico Medicine (INSIGNEO), University of Sheffield, Sheffield, United Kingdom
- Robert A. Lewis
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Robert A. Lewis
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- Krit Dwivedi
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Aqeeb Mahmood
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Jennifer Middleton
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Jennifer Middleton
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- Lisa Watson
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- Dheyaa Alkhanfar
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Christopher S. Johns
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Smitha Rajaram
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Pankaj Garg
- Norwich Medical School, University of East Anglia, Norwich, United Kingdom
- Robin Condliffe
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- Charlie A. Elliot
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- A. A. Roger Thompson
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- A. A. Roger Thompson
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- Alexander M. K. Rothman
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Alexander M. K. Rothman
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- Alexander M. K. Rothman
- Institute for in silico Medicine (INSIGNEO), University of Sheffield, Sheffield, United Kingdom
- Athanasios Charalampopoulos
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- Allan Lawrie
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Jim M. Wild
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Jim M. Wild
- Institute for in silico Medicine (INSIGNEO), University of Sheffield, Sheffield, United Kingdom
- Andrew J. Swift
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- Andrew J. Swift
- Institute for in silico Medicine (INSIGNEO), University of Sheffield, Sheffield, United Kingdom
- David G. Kiely
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- David G. Kiely
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- David G. Kiely
- Institute for in silico Medicine (INSIGNEO), University of Sheffield, Sheffield, United Kingdom
- DOI
- https://doi.org/10.3389/fcvm.2022.797561
- Journal volume & issue
-
Vol. 9
Abstract
BackgroundCurrent European Society of Cardiology and European Respiratory Society guidelines recommend regular risk stratification with an aim of treating patients with pulmonary arterial hypertension (PAH) to improve or maintain low-risk status (<5% 1-year mortality).MethodsConsecutive patients with PAH who underwent cardiac magnetic resonance imaging (cMRI) were identified from the Assessing the Spectrum of Pulmonary hypertension Identified at a Referral centre (ASPIRE) registry. Kaplan–Meier survival curves, locally weighted scatterplot smoothing regression and multi-variable logistic regression analysis were performed.ResultsIn 311 consecutive, treatment-naïve patients with PAH undergoing cMRI including 121 undergoing follow-up cMRI, measures of right ventricular (RV) function including right ventricular ejection fraction (RVEF) and RV end systolic volume and right atrial (RA) area had prognostic value. However, only RV metrics were able to identify a low-risk status. Age (p < 0.01) and RVEF (p < 0.01) but not RA area were independent predictors of 1-year mortality.ConclusionThis study highlights the need for guidelines to include measures of RV function rather than RA area alone to aid the risk stratification of patients with PAH.
Keywords
- pulmonary hypertension
- pulmonary arterial hypertension (PAH)
- right atrial area
- right ventricular (RV)
- risk stratification
- cardiac magnetic resonance imaging (cMRI)